Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: A retrospective clinical analysis
Omalizumab (anti-IgE) therapy is effective and safe in chronic urticaria (CU) in placebo-controlled clinical trials but real life clinical data are scarce.
Gespeichert in:
| Autor*in: |
Metz, Martin [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2014 |
|---|
| Schlagwörter: |
|---|
| Umfang: |
6 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Acceptability of a smartphone application with prenatal care at a federally qualified health center - Vani, Kavita ELSEVIER, 2022, the official journal of the Japanese Society for Investigative Dermatology, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:73 ; year:2014 ; number:1 ; pages:57-62 ; extent:6 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.jdermsci.2013.08.011 |
|---|
| Katalog-ID: |
ELV033988897 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV033988897 | ||
| 003 | DE-627 | ||
| 005 | 20230624002521.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180603s2014 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jdermsci.2013.08.011 |2 doi | |
| 028 | 5 | 2 | |a GBVA2014014000013.pica |
| 035 | |a (DE-627)ELV033988897 | ||
| 035 | |a (ELSEVIER)S0923-1811(13)00300-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.92 |2 bkl | ||
| 100 | 1 | |a Metz, Martin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: A retrospective clinical analysis |
| 264 | 1 | |c 2014 | |
| 300 | |a 6 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Omalizumab (anti-IgE) therapy is effective and safe in chronic urticaria (CU) in placebo-controlled clinical trials but real life clinical data are scarce. | ||
| 650 | 7 | |a Urticaria |2 Elsevier | |
| 650 | 7 | |a Omalizumab |2 Elsevier | |
| 650 | 7 | |a Clinical trials |2 Elsevier | |
| 650 | 7 | |a Mast cell |2 Elsevier | |
| 700 | 1 | |a Ohanyan, Tatevik |4 oth | |
| 700 | 1 | |a Church, Martin K. |4 oth | |
| 700 | 1 | |a Maurer, Marcus |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science |a Vani, Kavita ELSEVIER |t Acceptability of a smartphone application with prenatal care at a federally qualified health center |d 2022 |d the official journal of the Japanese Society for Investigative Dermatology |g Amsterdam [u.a.] |w (DE-627)ELV009048685 |
| 773 | 1 | 8 | |g volume:73 |g year:2014 |g number:1 |g pages:57-62 |g extent:6 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.jdermsci.2013.08.011 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 44.92 |j Gynäkologie |q VZ |
| 951 | |a AR | ||
| 952 | |d 73 |j 2014 |e 1 |h 57-62 |g 6 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
m m mm |
|---|---|
| matchkey_str |
metzmartinohanyantatevikchurchmartinkmau:2014----:mlzmbsnfetvadailatnteaynifclttethoiutcra |
| hierarchy_sort_str |
2014 |
| bklnumber |
44.92 |
| publishDate |
2014 |
| allfields |
10.1016/j.jdermsci.2013.08.011 doi GBVA2014014000013.pica (DE-627)ELV033988897 (ELSEVIER)S0923-1811(13)00300-9 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.92 bkl Metz, Martin verfasserin aut Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: A retrospective clinical analysis 2014 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Omalizumab (anti-IgE) therapy is effective and safe in chronic urticaria (CU) in placebo-controlled clinical trials but real life clinical data are scarce. Urticaria Elsevier Omalizumab Elsevier Clinical trials Elsevier Mast cell Elsevier Ohanyan, Tatevik oth Church, Martin K. oth Maurer, Marcus oth Enthalten in Elsevier Science Vani, Kavita ELSEVIER Acceptability of a smartphone application with prenatal care at a federally qualified health center 2022 the official journal of the Japanese Society for Investigative Dermatology Amsterdam [u.a.] (DE-627)ELV009048685 volume:73 year:2014 number:1 pages:57-62 extent:6 https://doi.org/10.1016/j.jdermsci.2013.08.011 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.92 Gynäkologie VZ AR 73 2014 1 57-62 6 045F 610 |
| spelling |
10.1016/j.jdermsci.2013.08.011 doi GBVA2014014000013.pica (DE-627)ELV033988897 (ELSEVIER)S0923-1811(13)00300-9 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.92 bkl Metz, Martin verfasserin aut Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: A retrospective clinical analysis 2014 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Omalizumab (anti-IgE) therapy is effective and safe in chronic urticaria (CU) in placebo-controlled clinical trials but real life clinical data are scarce. Urticaria Elsevier Omalizumab Elsevier Clinical trials Elsevier Mast cell Elsevier Ohanyan, Tatevik oth Church, Martin K. oth Maurer, Marcus oth Enthalten in Elsevier Science Vani, Kavita ELSEVIER Acceptability of a smartphone application with prenatal care at a federally qualified health center 2022 the official journal of the Japanese Society for Investigative Dermatology Amsterdam [u.a.] (DE-627)ELV009048685 volume:73 year:2014 number:1 pages:57-62 extent:6 https://doi.org/10.1016/j.jdermsci.2013.08.011 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.92 Gynäkologie VZ AR 73 2014 1 57-62 6 045F 610 |
| allfields_unstemmed |
10.1016/j.jdermsci.2013.08.011 doi GBVA2014014000013.pica (DE-627)ELV033988897 (ELSEVIER)S0923-1811(13)00300-9 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.92 bkl Metz, Martin verfasserin aut Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: A retrospective clinical analysis 2014 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Omalizumab (anti-IgE) therapy is effective and safe in chronic urticaria (CU) in placebo-controlled clinical trials but real life clinical data are scarce. Urticaria Elsevier Omalizumab Elsevier Clinical trials Elsevier Mast cell Elsevier Ohanyan, Tatevik oth Church, Martin K. oth Maurer, Marcus oth Enthalten in Elsevier Science Vani, Kavita ELSEVIER Acceptability of a smartphone application with prenatal care at a federally qualified health center 2022 the official journal of the Japanese Society for Investigative Dermatology Amsterdam [u.a.] (DE-627)ELV009048685 volume:73 year:2014 number:1 pages:57-62 extent:6 https://doi.org/10.1016/j.jdermsci.2013.08.011 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.92 Gynäkologie VZ AR 73 2014 1 57-62 6 045F 610 |
| allfieldsGer |
10.1016/j.jdermsci.2013.08.011 doi GBVA2014014000013.pica (DE-627)ELV033988897 (ELSEVIER)S0923-1811(13)00300-9 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.92 bkl Metz, Martin verfasserin aut Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: A retrospective clinical analysis 2014 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Omalizumab (anti-IgE) therapy is effective and safe in chronic urticaria (CU) in placebo-controlled clinical trials but real life clinical data are scarce. Urticaria Elsevier Omalizumab Elsevier Clinical trials Elsevier Mast cell Elsevier Ohanyan, Tatevik oth Church, Martin K. oth Maurer, Marcus oth Enthalten in Elsevier Science Vani, Kavita ELSEVIER Acceptability of a smartphone application with prenatal care at a federally qualified health center 2022 the official journal of the Japanese Society for Investigative Dermatology Amsterdam [u.a.] (DE-627)ELV009048685 volume:73 year:2014 number:1 pages:57-62 extent:6 https://doi.org/10.1016/j.jdermsci.2013.08.011 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.92 Gynäkologie VZ AR 73 2014 1 57-62 6 045F 610 |
| allfieldsSound |
10.1016/j.jdermsci.2013.08.011 doi GBVA2014014000013.pica (DE-627)ELV033988897 (ELSEVIER)S0923-1811(13)00300-9 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.92 bkl Metz, Martin verfasserin aut Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: A retrospective clinical analysis 2014 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Omalizumab (anti-IgE) therapy is effective and safe in chronic urticaria (CU) in placebo-controlled clinical trials but real life clinical data are scarce. Urticaria Elsevier Omalizumab Elsevier Clinical trials Elsevier Mast cell Elsevier Ohanyan, Tatevik oth Church, Martin K. oth Maurer, Marcus oth Enthalten in Elsevier Science Vani, Kavita ELSEVIER Acceptability of a smartphone application with prenatal care at a federally qualified health center 2022 the official journal of the Japanese Society for Investigative Dermatology Amsterdam [u.a.] (DE-627)ELV009048685 volume:73 year:2014 number:1 pages:57-62 extent:6 https://doi.org/10.1016/j.jdermsci.2013.08.011 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.92 Gynäkologie VZ AR 73 2014 1 57-62 6 045F 610 |
| language |
English |
| source |
Enthalten in Acceptability of a smartphone application with prenatal care at a federally qualified health center Amsterdam [u.a.] volume:73 year:2014 number:1 pages:57-62 extent:6 |
| sourceStr |
Enthalten in Acceptability of a smartphone application with prenatal care at a federally qualified health center Amsterdam [u.a.] volume:73 year:2014 number:1 pages:57-62 extent:6 |
| format_phy_str_mv |
Article |
| bklname |
Gynäkologie |
| institution |
findex.gbv.de |
| topic_facet |
Urticaria Omalizumab Clinical trials Mast cell |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Acceptability of a smartphone application with prenatal care at a federally qualified health center |
| authorswithroles_txt_mv |
Metz, Martin @@aut@@ Ohanyan, Tatevik @@oth@@ Church, Martin K. @@oth@@ Maurer, Marcus @@oth@@ |
| publishDateDaySort_date |
2014-01-01T00:00:00Z |
| hierarchy_top_id |
ELV009048685 |
| dewey-sort |
3610 |
| id |
ELV033988897 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV033988897</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624002521.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2014 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.jdermsci.2013.08.011</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2014014000013.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV033988897</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0923-1811(13)00300-9</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.92</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Metz, Martin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: A retrospective clinical analysis</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2014</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">6</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Omalizumab (anti-IgE) therapy is effective and safe in chronic urticaria (CU) in placebo-controlled clinical trials but real life clinical data are scarce.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Urticaria</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Omalizumab</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Clinical trials</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Mast cell</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ohanyan, Tatevik</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Church, Martin K.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Maurer, Marcus</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Vani, Kavita ELSEVIER</subfield><subfield code="t">Acceptability of a smartphone application with prenatal care at a federally qualified health center</subfield><subfield code="d">2022</subfield><subfield code="d">the official journal of the Japanese Society for Investigative Dermatology</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV009048685</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:73</subfield><subfield code="g">year:2014</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:57-62</subfield><subfield code="g">extent:6</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.jdermsci.2013.08.011</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.92</subfield><subfield code="j">Gynäkologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">73</subfield><subfield code="j">2014</subfield><subfield code="e">1</subfield><subfield code="h">57-62</subfield><subfield code="g">6</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Metz, Martin |
| spellingShingle |
Metz, Martin ddc 610 bkl 44.92 Elsevier Urticaria Elsevier Omalizumab Elsevier Clinical trials Elsevier Mast cell Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: A retrospective clinical analysis |
| authorStr |
Metz, Martin |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV009048685 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 610 VZ 44.92 bkl Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: A retrospective clinical analysis Urticaria Elsevier Omalizumab Elsevier Clinical trials Elsevier Mast cell Elsevier |
| topic |
ddc 610 bkl 44.92 Elsevier Urticaria Elsevier Omalizumab Elsevier Clinical trials Elsevier Mast cell |
| topic_unstemmed |
ddc 610 bkl 44.92 Elsevier Urticaria Elsevier Omalizumab Elsevier Clinical trials Elsevier Mast cell |
| topic_browse |
ddc 610 bkl 44.92 Elsevier Urticaria Elsevier Omalizumab Elsevier Clinical trials Elsevier Mast cell |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
t o to m k c mk mkc m m mm |
| hierarchy_parent_title |
Acceptability of a smartphone application with prenatal care at a federally qualified health center |
| hierarchy_parent_id |
ELV009048685 |
| dewey-tens |
610 - Medicine & health |
| hierarchy_top_title |
Acceptability of a smartphone application with prenatal care at a federally qualified health center |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV009048685 |
| title |
Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: A retrospective clinical analysis |
| ctrlnum |
(DE-627)ELV033988897 (ELSEVIER)S0923-1811(13)00300-9 |
| title_full |
Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: A retrospective clinical analysis |
| author_sort |
Metz, Martin |
| journal |
Acceptability of a smartphone application with prenatal care at a federally qualified health center |
| journalStr |
Acceptability of a smartphone application with prenatal care at a federally qualified health center |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2014 |
| contenttype_str_mv |
zzz |
| container_start_page |
57 |
| author_browse |
Metz, Martin |
| container_volume |
73 |
| physical |
6 |
| class |
610 610 DE-600 610 VZ 44.92 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Metz, Martin |
| doi_str_mv |
10.1016/j.jdermsci.2013.08.011 |
| dewey-full |
610 |
| title_sort |
omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis |
| title_auth |
Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: A retrospective clinical analysis |
| abstract |
Omalizumab (anti-IgE) therapy is effective and safe in chronic urticaria (CU) in placebo-controlled clinical trials but real life clinical data are scarce. |
| abstractGer |
Omalizumab (anti-IgE) therapy is effective and safe in chronic urticaria (CU) in placebo-controlled clinical trials but real life clinical data are scarce. |
| abstract_unstemmed |
Omalizumab (anti-IgE) therapy is effective and safe in chronic urticaria (CU) in placebo-controlled clinical trials but real life clinical data are scarce. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA |
| container_issue |
1 |
| title_short |
Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: A retrospective clinical analysis |
| url |
https://doi.org/10.1016/j.jdermsci.2013.08.011 |
| remote_bool |
true |
| author2 |
Ohanyan, Tatevik Church, Martin K. Maurer, Marcus |
| author2Str |
Ohanyan, Tatevik Church, Martin K. Maurer, Marcus |
| ppnlink |
ELV009048685 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth |
| doi_str |
10.1016/j.jdermsci.2013.08.011 |
| up_date |
2024-07-06T19:58:59.805Z |
| _version_ |
1803861035379064832 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV033988897</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624002521.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2014 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.jdermsci.2013.08.011</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2014014000013.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV033988897</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0923-1811(13)00300-9</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.92</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Metz, Martin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: A retrospective clinical analysis</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2014</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">6</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Omalizumab (anti-IgE) therapy is effective and safe in chronic urticaria (CU) in placebo-controlled clinical trials but real life clinical data are scarce.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Urticaria</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Omalizumab</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Clinical trials</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Mast cell</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ohanyan, Tatevik</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Church, Martin K.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Maurer, Marcus</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Vani, Kavita ELSEVIER</subfield><subfield code="t">Acceptability of a smartphone application with prenatal care at a federally qualified health center</subfield><subfield code="d">2022</subfield><subfield code="d">the official journal of the Japanese Society for Investigative Dermatology</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV009048685</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:73</subfield><subfield code="g">year:2014</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:57-62</subfield><subfield code="g">extent:6</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.jdermsci.2013.08.011</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.92</subfield><subfield code="j">Gynäkologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">73</subfield><subfield code="j">2014</subfield><subfield code="e">1</subfield><subfield code="h">57-62</subfield><subfield code="g">6</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.40018 |